首页> 美国卫生研究院文献>BMJ Open Diabetes Research Care >Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week randomized open-label extension of the PIONEER 7 trial

【2h】

Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week randomized open-label extension of the PIONEER 7 trial

机译：口腔半蛋白质的长期疗效和安全性以及从SitaGlittin转换为2型糖尿病患者的SitaGlittin到口腔半蛋白质的效果：A 52周随机开放标签延伸的先驱7试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

The PIONEER 7 trial demonstrated superior glycemic control and weight loss with once-daily oral semaglutide with flexible dose adjustment versus sitagliptin 100 mg in type 2 diabetes. This 52-week extension evaluated long-term oral semaglutide treatment and switching from sitagliptin to oral semaglutide.

机译：先驱7试验表现出优异的血糖控制和体重减轻，用柔性剂量调节与2型糖尿病患者的SITAGLIPTIN 100mg。该52周的扩展评估了长期口服半蛋白质处理和从SitaGliptin切换到口腔半蛋白质。

著录项

期刊名称 BMJ Open Diabetes Research Care
作者
John B Buse; Bruce W Bode; Ann Mertens; Young Min Cho; Erik Christiansen; Christin L Hertz; Morten A Nielsen; Thomas R Pieber;
展开▼
作者单位

展开▼
年(卷),期 2020(8),2
年度 2020
页码 e001649
总页数 13
原文格式 PDF
正文语种
中图分类心血管疾病;
关键词
glucagon-like peptide 1; dipeptidyl peptidase 4; treatment outcome;

机译：胰高血糖素肽1;二肽基肽酶4;治疗结果;

相似文献

外文文献
专利

1. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial (vol 7, pg 528, 2019) [J] . Pieber T. R., Bode B., Mertens A. The lancet. Diabetes & endocrinology. . 2019,第9期

机译：口腔半蛋白质的疗效和安全性具有柔性剂量调节与2型糖尿病（先锋7）：多期，开放标签，随机，第3A阶段试验（Vol 7，PG 528,2019）
2. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial [J] . Pieber Thomas R., Bode Bruce, Mertens Ann, The lancet. Diabetes & endocrinology. . 2019,第7期

机译：口腔半蛋白质具有柔性剂量调节的功效和安全性与2型糖尿病（先锋7）的SITAGLIPTIN：多期，开放标签，随机，第3A期试验
3. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial [J] . The lancet. Diabetes & endocrinology. . 2020,第5期

机译：2型糖尿病患者口腔半蛋白质单疗法的剂量 - 反应，疗效和安全性（先锋9）：52周，第2/3A期，随机，受控试验
4. A series of open-label studies comparing various formulations of orally administeredinsulin (Oralin) in patients with Type -1 Diabetes Mellitus (DM) [C] . Jaime Guevara-Aguirre, Marco Guevara, Jeannette Saavedra Annual meeting exposition of the Controlled Release Society . 2005

机译：一系列开放标签研究比较了-1型糖尿病（DM）患者口服胰岛素（Oralin）的各种配方
5. A randomized, open-label, intervention study to evaluate the effect of diet composition on weight gain in obese, type 2 diabetes patients receiving intensive insulin therapy. [D] . Villareal, Roland. 2008

机译：一项随机，开放标签，干预性研究，以评估饮食结构对接受强化胰岛素治疗的肥胖2型糖尿病患者体重增加的影响。
6. Efficacy Safety and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial [O] . Bernard Zinman, Vanita R. Aroda, John B. Buse, 2019

机译：口腔半蛋白质的功效安全性和耐受性在2型糖尿病患者中添加或没有二甲双胍的胰岛素患者：先驱8试验
7. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial [O] . Thomas R Pieber, Bruce Bode, Ann Mertens, 2019

机译：口腔半蛋白质具有柔性剂量调节的疗效和安全性与2型糖尿病（先锋7）的SITAGLIPTIN：多期，开放标签，随机，第3A期试验

Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week randomized open-label extension of the PIONEER 7 trial

摘要

著录项

相似文献

相关主题

期刊订阅